377 related articles for article (PubMed ID: 30121013)
1. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
[TBL] [Abstract][Full Text] [Related]
2. Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation.
Zhu C; Guo X; Luo L; Wu Z; Luo Z; Jiang M; Zhang J; Qin B; Shi Y; Lou Y; Qiu Y; You J
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46536-46547. PubMed ID: 31751119
[TBL] [Abstract][Full Text] [Related]
3. Sequential Intercellular Delivery Nanosystem for Enhancing ROS-Induced Antitumor Therapy.
Wang B; Zhang H; An J; Zhang Y; Sun L; Jin Y; Shi J; Li M; Zhang H; Zhang Z
Nano Lett; 2019 Jun; 19(6):3505-3518. PubMed ID: 31034238
[TBL] [Abstract][Full Text] [Related]
4. Fullerene (C60)-based tumor-targeting nanoparticles with "off-on" state for enhanced treatment of cancer.
Shi J; Wang B; Wang L; Lu T; Fu Y; Zhang H; Zhang Z
J Control Release; 2016 Aug; 235():245-258. PubMed ID: 27276066
[TBL] [Abstract][Full Text] [Related]
5. Enhanced drug delivery using sonoactivatable liposomes with membrane-embedded porphyrins.
Wang X; Yan F; Liu X; Wang P; Shao S; Sun Y; Sheng Z; Liu Q; Lovell JF; Zheng H
J Control Release; 2018 Sep; 286():358-368. PubMed ID: 30075210
[TBL] [Abstract][Full Text] [Related]
6. An Implantable Depot That Can Generate Oxygen in Situ for Overcoming Hypoxia-Induced Resistance to Anticancer Drugs in Chemotherapy.
Huang CC; Chia WT; Chung MF; Lin KJ; Hsiao CW; Jin C; Lim WH; Chen CC; Sung HW
J Am Chem Soc; 2016 Apr; 138(16):5222-5. PubMed ID: 27075956
[TBL] [Abstract][Full Text] [Related]
7. ROS-sensitive thioketal-linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy.
Pei P; Sun C; Tao W; Li J; Yang X; Wang J
Biomaterials; 2019 Jan; 188():74-82. PubMed ID: 30336287
[TBL] [Abstract][Full Text] [Related]
8. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting Hypoxia and Chemotherapy-Induced Cancer Cell Metastasis under a Valid Therapeutic Effect by an Assistance of Biomimetic Oxygen Delivery.
Jiang MS; Yin XY; Qin B; Xuan SY; Yuan XL; Yin H; Zhu C; Li X; Yang J; Du YZ; Luo LH; You J
Mol Pharm; 2019 Nov; 16(11):4530-4541. PubMed ID: 31617723
[TBL] [Abstract][Full Text] [Related]
10. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
Li Y; Luo J; Lin MT; Zhi P; Guo WW; Han M; You J; Gao JQ
Mol Pharm; 2019 Jul; 16(7):2966-2979. PubMed ID: 31095914
[TBL] [Abstract][Full Text] [Related]
11. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma.
Liu H; Xie Y; Zhang Y; Cai Y; Li B; Mao H; Liu Y; Lu J; Zhang L; Yu R
Biomaterials; 2017 Mar; 121():130-143. PubMed ID: 28088075
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor effect of doxorubicin by its complexation with gamma-cyclodextrin in pegylated liposomes.
Arima H; Hagiwara Y; Hirayama F; Uekama K
J Drug Target; 2006 May; 14(4):225-32. PubMed ID: 16777681
[TBL] [Abstract][Full Text] [Related]
13. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
14. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
15. Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species.
Xu L; Zhang Z; Ding Y; Wang L; Cheng Y; Meng L; Wu J; Yuan A; Hu Y; Zhu Y
Biomater Sci; 2019 Nov; 7(11):4782-4789. PubMed ID: 31524211
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.
Dicheva BM; ten Hagen TL; Seynhaeve AL; Amin M; Eggermont AM; Koning GA
Pharm Res; 2015 Dec; 32(12):3862-76. PubMed ID: 26202516
[TBL] [Abstract][Full Text] [Related]
17. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
18. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
19. Molecular structural transformation regulated dynamic disordering of supramolecular vesicles as pH-responsive drug release systems.
Liu Y; Gao FP; Zhang D; Fan YS; Chen XG; Wang H
J Control Release; 2014 Jan; 173():140-7. PubMed ID: 24188958
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose.
Luo Z; Tian H; Liu L; Chen Z; Liang R; Chen Z; Wu Z; Ma A; Zheng M; Cai L
Theranostics; 2018; 8(13):3584-3596. PubMed ID: 30026868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
